| Type | Title | Date Released | |
|---|---|---|---|
10-Q | Form 10-Q | ||
8-K | Korro Reports Third Quarter 2026 Financial Results and Provides Corporate Update | ||
SCHEDULE 13G/A | BlackRock, Inc. (Filed by) | ||
4 | Nichols Weston (Reporting) | ||
8-K | Preclinical KRRO-111 Data Showed 95% SERPINA1 Editing and Reduced Liver Z-AAT by 95%, Supporting Dual Lung-Liver AATD Potential | ||
8-K | Korro Bio Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121 | ||
4 | FORMELA JEAN FRANCOIS (Reporting) | ||
144 | Form 144 | ||
144 | Form 144 | ||
4 | Dolan Oliver (Reporting) | ||
144 | Form 144 | ||
144 | Form 144 |
